KLK3 and benign prostatic hyperplasia: Currently, the detection of prostate-specific antigen (PSA), a biomarker for the prognosis of CRPC, is criticized for its low accuracy, false-positive rate, and high invasiveness due to infection, trauma, and benign prostatic hyperplasia [5,6].